Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Adopting New Marketing Push For Avandia

This article was originally published in The Pink Sheet Daily

Executive Summary

ADOPT trial results, which show rosiglitazone beats metformin for maintaining glycemic control, could double the market for the insulin sensitizer.

You may also be interested in...



GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women

FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.

GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women

FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.

Avandia Not Losing Market Share To Januvia, GSK Reports

Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel